文献速递妇科

替索单抗维多汀相关眼部事件的风险降低与管理策略

Mitigation and management strategies for ocular events associated with tisotumab vedotin.
PubMed 文献 · Gynecol Oncol · 2022-03-08

替索单抗维多汀是靶向组织因子的抗体偶联药物,用于复发或转移性宫颈癌。innovaTV 204 研究中 101 例患者中 54 例(53%)出现 138 起眼部治疗相关不良事件,多为 1-2 级,以结膜炎、干眼和角膜炎最常见,经眼科护理和剂量调整多可管理。

要点

  • 眼部治疗相关不良事件多为 1-2 级,常见结膜炎、干眼和角膜炎。
  • 基于临床试验经验制定眼护理计划,包括基线及每次给药前眼科检查。
  • 已制定剂量调整指南以管理潜在眼部不良事件。

核心结论

  • 通过密切监测早期体征和症状、严格遵守眼护理、出现眼部不良事件时给予药物干预以及必要时调整剂量,可早期发现眼部不良事件并在影响视力前缓解症状,最终帮助患者坚持治疗。

研究设计与样本

  • 基于关键 2 期研究 innovaTV 204 的临床试验经验,101 例复发或转移性宫颈癌患者接受替索单抗维多汀治疗。

主要发现

  • 54 例(53%)患者观察到 138 起眼部治疗相关不良事件,主要为 1 级或 2 级。
  • 最常见的眼部治疗相关不良事件为结膜炎(26 例[26%])、干眼(23 例[23%])和角膜炎(11 例[11%])。
  • 138 起眼部治疗相关不良事件中 118 起(86%)在末次替索单抗维多汀给药后 30 天内缓解,中位缓解时间为 0.7 个月(四分位距:0.3-1.6)。

关键数值与推荐

  • 眼护理计划包括:肿瘤护理团队与眼科护理提供者合作,基线时(按试验缓解措施)和每次给药前进行眼科检查,使用眼药水和冷敷,避免使用隐形眼镜,并建议出现新发或加重的眼部体征和症状时及时转诊。
  • 已制定剂量调整指南以管理潜在眼部不良事件。

临床怎么用

  • 肿瘤科医生应熟悉通常出现的症状,眼科护理提供者应成为治疗接受替索单抗维多汀患者的综合护理团队中不可或缺的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate developed for treatment of recurrent or metastatic cervical cancer (r/mCC). In the pivotal phase 2 study innovaTV 204, 101 r/mCC patients received tisotumab vedotin. 138 ocular treatment-related AEs (TRAEs), predominantly Grade 1 or 2, were observed in 54 (53%) patients. The most common ocular TRAEs were conjunctivitis (26 patients [26%]), dry eye (23 patients [23%]), and keratitis (11 patients [11%]). Observed ocular TRAEs are hypothesized to be conjunctival and inflammatory in nature, resulting in signs and symptoms readily recognizable by patients and healthcare providers. Generally, ocular TRAEs were manageable with ophthalmic care (prophylactic and symptom management) and dose modifications. Of 138 ocular TRAEs, 118 (86%) resolved within 30 days after last dose of tisotumab vedotin. Median time to resolution was 0.7 months (interquartile range: 0.3-1.6). To help reduce the risk of ocular AEs, an eye care plan based on clinical trial experience was developed. This encompasses an oncology care team partnering with an eye care provider, incorporates eye exams at baseline (per trial mitigation measures) and prior to each dose, includes eye drops and cold packs, avoids contact lens use, and advises prompt referral for new or worsening ocular signs and symptoms. Moreover, dose modification guidelines have been developed to manage potential ocular AEs. Ocular AEs will require patient management strategies that may be new to oncology teams. Oncologists should become familiar with symptoms that typically arise, and eye care providers should be an integral part of the comprehensive care team treating patients receiving tisotumab vedotin. With diligent monitoring for early signs and symptoms, careful adherence to required eye care, pharmacologic intervention when ocular AEs arise, and dose modifications when needed, ocular AEs can be detected early and symptoms can be alleviated before any impact on vision, to ultimately help patients stay on therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SK, Ursell P, Coleman RL, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022. PMID: 35277279. doi:10.1016/j.ygyno.2022.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。